Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
60.7M
-
Number of holders
-
67
-
Total 13F shares, excl. options
-
38.4M
-
Shares change
-
-4.77M
-
Total reported value, excl. options
-
$148M
-
Value change
-
-$20.5M
-
Put/Call ratio
-
1.22
-
Number of buys
-
45
-
Number of sells
-
-25
-
Price
-
$3.84
Significant Holders of Acumen Pharmaceuticals, Inc. - Common stock, par value $0.0001 per share (ABOS) as of Q4 2023
91 filings reported holding ABOS - Acumen Pharmaceuticals, Inc. - Common stock, par value $0.0001 per share as of Q4 2023.
Acumen Pharmaceuticals, Inc. - Common stock, par value $0.0001 per share (ABOS) has 67 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38.4M shares
of 60.7M outstanding shares and own 63.37% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (14.9M shares), Sands Capital Ventures, LLC (3.42M shares), FRANKLIN RESOURCES INC (3.36M shares), Rock Springs Capital Management LP (2.3M shares), Laurion Capital Management LP (1.9M shares), VANGUARD GROUP INC (1.84M shares), Knollwood Investment Advisory, LLC (1.63M shares), MILLENNIUM MANAGEMENT LLC (1.5M shares), Alyeska Investment Group, L.P. (733K shares), and JANE STREET GROUP, LLC (605K shares).
This table shows the top 67 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.